Notice of Change to PA-25-169, "Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)"
Notice Number:
NOT-EB-25-007
Key Dates
Release Date:
June 16, 2025
Related Announcements
- January 08, 2025 - Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional). See PA-25-169.
Issued by
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Eye Institute (NEI)
National Institute on Aging (NIA)
Purpose
The purpose of this Notice is to add an additional due date for PA-25-169 "Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)."
The following section has been modified to reflect changes to the due date for new applications:
Part 1. Overview Information, Key Dates
Corrected to read (in bold italics):
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| October 16, 2025 | November 16, 2025 | January 07, 2025 | March 2026 | May 2026 | July 2026 |
| February 16, 2026 | March 16, 2026 | May 07, 2026 | July 2026 | October 2026 | December 2026 |
Expiration Date: May 08, 2026
All other aspects of the NOFO remain unchanged. These changes are effective immediately.
Inquiries
Please direct all inquiries to:
Randy King, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-0707
Email: [email protected]
Department of Health
and Human Services (HHS)
and Human Services (HHS)
